Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy1601
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma140
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort133
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience129
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review128
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma122
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma117
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma112
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation105
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib103
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT99
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study99
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy96
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review92
Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy91
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study91
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma77
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report76
MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma74
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence72
Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia71
Genomic landscape of hyperleukocytic acute myeloid leukemia71
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease68
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas63
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)63
B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation63
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells61
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT61
Clinical features and outcomes in primary nervous system histiocytic neoplasms61
Sensitive multiple myeloma disease monitoring by mass spectrometry61
Genetically determined telomere length and multiple myeloma risk and outcome60
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement58
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia57
Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning56
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms53
Spatial phenotyping of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma53
Disparities in time to treatment with oral antimyeloma medications52
Cost comparison of post-remission strategies in younger and older AML patients in France48
Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience48
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib46
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach46
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries45
Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients43
0.040354013442993